Home / Pharmaceuticals / Asthma And COPD Drugs Market By Drug Type (Anti-Inflammatory Drugs, Bronchodilator Monotherapy, Combination Drugs, Pipeline Analysis) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

Asthma And COPD Drugs Market By Drug Type (Anti-Inflammatory Drugs, Bronchodilator Monotherapy, Combination Drugs, Pipeline Analysis) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

Published: Jun 2017 | Report Code: 58486-06-17

Asthma is chronic respiratory disease that causes inflammation of narrowing of airways. COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that makes breathing difficult including chronic bronchitis and emphysema and that gets worse with time. COPD is one of the leading cause of mortality and morbidity worldwide, with prevalence rate of 5-13%. Prevalence rate is directly proportional to increase in smoking rates and air population, especially in developing countries. Both for asthma and COPD, new pharmacologic options have being explored, by focusing on specific biological mechanisms knowing the pathogenesis of these diseases. Thus, with entrant of novel drugs may offer better treatment options. Though the generic entry of drug might affect the market, slowing the growth of the market. With key players innovating novel combination therapies, use of biologics, personalization treatment would drive the asthma and COPD drugs market.

The report titled “Asthma and COPD Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall asthma and COPD drugs market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global asthma and COPD drugs market are majorly segmented into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergics.

Geographically, the global asthma and COPD drugs market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global asthma and COPD drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global asthma and COPD drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global asthma and COPD drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Asthma And COPD Drugs Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Asthma and COPD Market Portraiture
2.2 Global Asthma and COPD Market Share, by Drug type, 2016 Vs 2025 (Value %)
2.3 Global Asthma and COPD Market, by Geography, 2016 (Value %)

Chapter 3 Global Asthma and COPD Market Analysis
3.1 Global Asthma and COPD Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Asthma and COPD Market

Chapter 4 Global Asthma and COPD Market Analysis, by Drug Type, 2015-2025 (US$ Mn)
4.1 Introduction
4.2 Anti-inflammatory drugs
4.2.1 Corticosteroids
4.2.2 Anti-Leukotrienes
4.2.3 Monoclonal antibodies
4.3 Bronchodilator monotherapy
4.3.1 Short-acting beta2-agonist (SABAs)
4.3.2 Long-acting beta2-agonist (LABAs)
4.3.3 Anticholinergics
4.4 Combination drugs
4.5 Pipeline Analysis
4.5.1 Projected sales of Phase III Asthma/COPD Drugs estimated till 2025 (US$ Mn)
4.5.1.1 GSK/INNOVIVA Fluticasone Furoate + Umeclidinium + Vilanterol (COPD)
4.5.1.2 Novartis Fevipiprant (Asthma)
4.5.1.3 Astrazeneca Tralokinumab (Asthma)
4.5.1.4 AstraZeneca/Kyowa Hakko Kirin Benralizumab (Asthma)
4.5.1.5 AstraZeneca Budesonide + formoterol (COPD)
4.5.1.6 AstraZeneca Budesonide + formoterol + glycopyrrolate (COPD)
4.5.1.7 AB Science Masitinib (Asthma)
4.5.1.8 GlaxoSmithKline Vilanterol (COPD)
4.5.1.9 Regeneron/Sanofi Dupilumab (Asthma)
4.5.1.10 Sunovion Sun-101(COPD)
4.5.1.11 Theravance Biopharma/Mylan Revefenacin (COPD)
4.5.1.12 Others
4.5.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Asthma and COPD Market, By Geography, 2015-2025 (US$ Mn)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, & Rest of APAC)
5.5 Latin America (Brazil, Mexico & Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Novartis AG
6.2 Merck & Co
6.3 Glaxosmithkline Plc
6.4 Boehringer Ingelheim Gmbh
6.5 Nycomed
6.6 Abbott Laboratories
6.7 AstraZeneca
6.8 Roche Holding AG
6.9 Teva Pharmaceutical Industries
6.10 Vectura Group
6.11 Pfizer Inc.

List Of Table : 

TABLE 1 Global Asthma and COPD Market, By Product Type 2015-2025 (US$ Mn)
TABLE 2 Global Antibody Tests Market, 2015-2025 (US$ Mn)
TABLE 1 Global HIV-1 Antibody Confirmatory Tests Market 2015-2025 (US$ Mn)
TABLE 1 Global Viral Identification testing Market 2015-2025 (US$ Mn)
TABLE 2 Global Asthma and COPD Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Asthma and COPD Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 4 Europe Asthma and COPD Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Asia-Pacific Asthma and COPD Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 7 Abbvie Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 8 Alere Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 9 Apogee Flow Systems: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 10 Beckman Coulter, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Becton, Dickinson & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 12 BD Biosciences: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Bio-Rad Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 BioMerieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Cepheid: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Chembio Diagnostic Systems: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Daktari Diagnostics: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Gilead Sciences: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Gilead Sciences: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Merch & Co. Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Mylan Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 Janssen Therapeutics: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

List Of Figures : 

FIG. 1 Global Asthma and COPD Market: Research Methodology
FIG. 2 Global Asthma and COPD Market Share, by Product type, 2016 Vs 2025 (Value %)
FIG. 3 Global Asthma and COPD Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Asthma and COPD Market, by Geography
FIG. 5 Competitive Analysis: Key Players in Global Asthma and COPD Market
FIG. 6 Global HIV-1 Screening Tests Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global ELISA Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Rapid Tests Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Home Access Dried Blood Spots Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Western Blot Tests Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Indirect Immunofluorescence Assays (IFA) Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Line Immunoassays Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Radio-Immunoprecipitation Assays Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global P24 Antigen Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Qualitative PCR Test Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Viral Culture Market, 2015 – 2025 (US$ Mn)
FIG. 17 Global HIV-2 & Group O Diagnostic Tests Market, 2015 – 2025 (US$ Mn)
FIG. 18 Global Viral Load Tests Market, 2015 – 2025 (US$ Mn)
FIG. 19 Global CD4 Testing Market, 2015 – 2025 (US$ Mn)
FIG. 20 Global Early Infant Diagnostics Market, 2015 – 2025 (US$ Mn)
FIG. 21 Latin America Asthma and COPD Market, 2015 – 2025 (US$ Mn)
FIG. 22 Middle East & Africa Asthma and COPD Market, 2015 – 2025 (US$ Mn)

Based on the type of drugs, the global asthma and COPD market is segmented as follows:

  • Anti-inflammatory drugs
    • Corticosteroids
    • Anti-Leukotrienes
    • Monoclonal antibodies
  • Bronchodilator monotherapy
    • Short-acting beta2-agonist (SABAs)
    • Long-acting beta2-agonist (LABAs)
    • Anticholinergics
  • Combination drugs

Currently treatment available for asthma and COPD includes anti-inflammatory drugs bronchodilator monotherapy and combination therapy, among which combination therapy dominates the market. The most favoured combination preferred for treatment are long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) combination that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline). The combination most preferred due to better efficacy and convenient delivery mechanism, and decreased side effects. Singulair, Seretide and Spiriva are commonly used medication for treatment of asthma and COPD in the US and Europe. Further, with increase in use of corticosteroids in combination with bronchodilators would drive the treatment market of asthma and COPD. Recent treatments such as combination products once-a-daily and monoclonal antibodies will create new growth opportunity for the market. There are many undergoing studies at various stage of development in pipeline. Pharmaceutical companies have being investing heavily in research and development of new biologics with help of biotechnology which would create immense market opportunities for sustainable development of the asthma and COPD market. Novartis' immunoglobulin E (IgE) inhibitor Xolair (omalizumab) is the only biologics available in the market currently for treatment of asthma. Benralizumab Astrazenca’s first biologics is expected to enter the market next year that would create new wave for use of biologics for treatment of asthma.

Asthma And COPD Drugs Market

For the purpose of this study, the global asthma and COPD market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Asthma And COPD Drugs Market

At present, North America dominates the global asthma and COPD market followed by the European market. The major drivers for the North American market are rising prevalence of asthma and COPD, technological advancements in treatment, delay in the influx of generics, and strong pipeline of novel therapies. Prevalence of asthma and COPD is increasing in developed countries due to smoking, sedentary lifestyle, obesity, genetic factors, etc. Rise in the demand of the treatment and high cost of treatment also contribute to market growth. Asia-Pacific is anticipated to be the fastest growing market during the forecast period. In emerging countries such as China, India, and others there is increase in the incidences of asthma and other respiratory diseases due to rise in pollution, urbanization, sedentary lifestyle, and prolonged life expectancy.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients